Table 6.
RRs and 95% CIs of the summary estimate, subsets and sensitivity analyses for the association between cryptorchidism and prenatal exposure to estrogenic agents.
| Subset of studies | No. of studies included | Mantel–Haenszel method (fixed effects) | χ2p-Value | DerSimonian–Laird method (random effects) |
|---|---|---|---|---|
| All studies | 6 | 1.34 (0.96–1.87) | 0.44 | 1.22 (0.86–1.73) |
| Excluding DES exposure | 3 | 1.06 (0.70–1.59) | 0.95 | 1.05 (0.70–1.59) |
| Studies including DES | 3 | 2.09 (1.13–3.86) | 0.24 | 1.80 (0.83–3.93) |
| Pharmaceutical estrogens | 5 | 1.44 (0.99–2.10) | 0.37 | 1.31 (0.87–1.96) |
| Pharmaceutical extrogens excluding DES | 2 | 1.10 (0.49–2.49) | 1 | 1.10 (0.49–2.49) |
| Case–control studies | 4 | 1.45 (0.98–2.15) | 0.24 | 1.38 (0.81–2.34) |
| Cohort studies | 2 | 1.04 (0.53–2.02) | 0.79 | 1.03 (0.53–2.00) |
| American studies | 4 | 1.55 (1.00–2.39) | 0.24 | 1.40 (0.82–2.41) |
| Excluding highest risk ratio | 5 | 1.21 (0.86–1.72) | 0.66 | 1.16 (0.81–1.66) |
| Excluding lowest risk ratio | 5 | 1.38 (0.97–1.97) | 0.34 | 1.27 (0.86–1.87) |
| Excluding highest weight | 5 | 1.46 (0.97–2.19) | 0.32 | 1.30 (0.82–2.06) |
| Excluding lowest weight | 5 | 1.21 (0.86–1.72) | 0.66 | 1.16 (0.81–1.66) |
| Excluding studies with quality score < 30 | 4 | 1.25 (0.86–1.80) | 0.53 | 1.19 (0.82–1.73) |
| Excluding studies with quality score < 35 | 3 | 1.06 (0.70–1.59) | 0.95 | 1.05 (0.70–1.59) |